Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 18/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 8/20 | 0.39 |
| ▸ | CA12 | O43570 | 7/20 | 0.39 |
| ▸ | CA9 | Q16790 | 7/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23531699 | 0.79 | DAO (0.42) | DAO | |
| SCHEMBL21321761 | 0.79 | CA2 (0.43) | CA2CA1CA12CA9CA4 | |
| SCHEMBL10373558 | 0.72 | CA2 (0.45) | CA2CA1CA12CA9CA4 | |
| SCHEMBL24978356 | 0.72 | CA2 (0.49) | CA2CA1CA12CA9CA4 | |
| SCHEMBL23569856 | 0.71 | CA2 (0.47) | CA2DAOCA1CA12CA9 | |
| SCHEMBL4802533 | 0.70 | CA2 (0.53) | CA2CA1CA12CA9CA4 | |
| SCHEMBL5153269 | 0.69 | CA2 (0.48) | CA2CA1CA12CA9CA4 | |
| SCHEMBL21962282 | 0.68 | CA2 (0.36) | CA2CA1CA12CA9CA4 | |
| SCHEMBL8870484 | 0.67 | CA2 (0.52) | CA2CA1CA12CA9CA4 | |
| SCHEMBL185767 | 0.67 | PTGES2 (0.53) | CA2CA1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1863789-B | Substituted isoquinolinones | PORTOLA PHARM INC | 2010-06-09 | — | — | CN | disclosed |
| EP-1667989-A4 | SUBSTITUTED ISOQUINOLINONES | PORTOLA PHARM INC (US) | 2008-08-20 | — | — | EP | disclosed |
| US-7294635-B2 | Substituted isoquinolinones | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| CN-1863789-A | Substituted isoquinolinones | PORTOLA PHARM INC (US) | 2006-11-15 | — | — | CN | disclosed |
| EP-1667989-A1 | SUBSTITUTED ISOQUINOLINONES | Portola Pharmaceuticals, Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050113399-A1 | Substituted isoquinolinones | PORTOLA PHARMACEUTICALS, INC. (US) | 2005-05-26 | — | — | US | disclosed |
| WO-2005035520-A1 | SUBSTITUTED ISOQUINOLINONES | PORTOLA PHARMACEUTICALS, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113399-A1 | Substituted isoquinolinones | PFKP, MPL, TBXA2R | CA2 4801/4885DAO 2528/4885CA1 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.